Core Viewpoint - Tiger Med's stock price has experienced a decline of 6.87% year-to-date, with significant drops in recent trading periods, indicating potential challenges in the market despite a recent uptick in share price [1][2]. Group 1: Stock Performance - On November 24, Tiger Med's stock rose by 2.02%, reaching 50.59 CNY per share, with a trading volume of 169 million CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 43.559 billion CNY [1]. - Year-to-date, the stock has decreased by 6.87%, with a drop of 8.98% over the last five trading days, 5.21% over the last 20 days, and 23.83% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion CNY, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion CNY [2]. - The company has distributed a total of 2.458 billion CNY in dividends since its A-share listing, with 1.154 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period [2]. - The largest shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares to 48.3625 million shares, and other notable shareholders such as China Europe Medical Health Mixed A and Huabao Zhongzheng Medical ETF [3].
泰格医药涨2.02%,成交额1.69亿元,主力资金净流入628.72万元